Skip to main content
Medical information Clinical review pending

Genetic Testing

BCRABL Minor Quantitative Test

The BCRABL Minor Quantitative Test monitors treatment effectiveness and detects potential relapse in patients with Chronic Myeloid Leukemia (CML).

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Whole Blood, Culture Cells, or Bone Marrow Aspirations.
Results
Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. Patients are required to sign a consent document and provide relevant clinical history.
Test priceKSh 20,400

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the BCRABL Minor Quantitative Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Monitoring treatment effectiveness for CML
  • ✓Detecting minimal residual disease (MRD) in CML
  • ✓Assessing risk of CML relapse
  • ✓Guiding treatment decisions in CML
  • ✓Evaluating response to tyrosine kinase inhibitors (TKIs)
02

In plain language

What this test helps you understand

Monitors treatment response in Chronic Myeloid Leukemia (CML) patients. Detects minimal residual disease (MRD) and potential relapse.
The BCRABL Minor Quantitative Test is a specialized diagnostic test used primarily for patients diagnosed with Chronic Myeloid Leukemia (CML). This test plays a critical role in monitoring the effectiveness of treatment and detecting any potential relapse. By measuring the levels of the BCR-ABL fusion gene, healthcare providers can tailor treatment plans to ensure optimal patient outcomes.

This test specifically detects the presence and quantity of the BCR-ABL fusion gene, which is a marker for CML. It provides quantitative results that help assess how well the treatment is working and whether adjustments are needed.

Patients diagnosed with CML should consider the BCRABL Minor Quantitative Test, especially if they are undergoing treatment. Symptoms that may prompt this test include fatigue, unexplained weight loss, night sweats, and frequent infections. Additionally, those with a family history of CML or other risk factors may also benefit from this test.

Benefits of taking the test include monitoring treatment effectiveness, detecting potential relapses early, guiding adjustments in therapy, and providing peace of mind for patients and families.

Results from the BCRABL Minor Quantitative Test will indicate the level of the BCR-ABL gene present in the blood. A decrease in levels typically suggests that the treatment is effective, while stable or increasing levels may indicate a need for further intervention. Always consult with your physician to interpret these results accurately.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Patients are required to sign a consent document and provide relevant clinical history.
SampleWhole Blood, Culture Cells, or Bone Marrow Aspirations.
MethodologyConfirm with the laboratory before booking. Typically involves molecular techniques like quantitative PCR (qPCR) to measure BCR-ABL transcript levels.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the BCR-ABL fusion gene but does not provide information on other genetic mutations or disease characteristics. Results must be interpreted in the context of the patient's overall clinical picture.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Chronic Myeloid Leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the body. It is characterized by the presence of the BCR-ABL fusion gene.
This test helps doctors monitor how well the CML treatment is working by measuring the amount of the BCR-ABL gene. It can detect the disease early if it starts to return.
The test measures the quantity of the BCR-ABL fusion gene in a blood or bone marrow sample. Lower levels generally indicate a better response to treatment.
The frequency of testing depends on your individual treatment plan and response. Your doctor will advise on the appropriate schedule.
A sample of whole blood, cultured cells, or bone marrow aspiration is required for this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp